[ad_1]
New early data from Grail showed that his liquid biopsy test was not only able to detect the presence of 12 different types of cancer at an early stage, but also to locate the disease in the body before it spreads using the signatures found in the blood.
The test also showed a very low rate of false positives, at 1% or less. Former Fierce Award winner 15 presented the results of a sub-study of his Cell-free Circulating Genome Atlas (GCGA) project at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago .
Detection rates ranged from a dozen predefined and potentially fatal tumor types to earlier stages – from 59% in lung cancers to 86% in head and neck cancers. Analyzed by stage of cancer, the test showed sensitivity rates of 34%, 77%, 84% and 92% for all types of tumors, stage I to stage IV, respectively.
In addition, results on the tissues of origin were provided for 94% of all detected cancers, the identifications being correct in 90% of the cases. With these results, the company is now considering moving its multicancer blood test further to the market.
"The data presented at ASCO suggest that the Grail test detects preferentially the most deadly cancers and can detect tumors when they are still localized and likely to be effectively treated," he said. said Grail's founder and director, Rick Klausner.
RELATED: The Seed of the Seed, watermark of the FDA's designation, turns eyes toward DNA methylation for early detection of cancer
"The high detection rate of stage II cancers, at 77% in the group of 12 fatal cancers, is particularly convincing and reinforces the potential benefit of our multi-cancerous approach," said Klausner, former director of the group. National Cancer Institute of the National Institutes of Health. .
The 12 types of study cancer and test sensitivity rates for detecting stage I-III disease were as follows: anorectal (79%), colorectal (74%), esophageal (76%), gastric (78%), head and neck (86%). ), hormone receptor-negative breast tumors (64%), liver tumors (68%), pulmonary tumors (59%), ovarian tumors (67%) and pancreatic tumors (78%), as well as multiple myelomas (71%) and lymphomas (70%) %). ), excluding leukemias.
According to Grail, these types of cancer account for nearly two-thirds of all cancer deaths in the United States, with the test demonstrating an overall detection rate of 76% at all stages.
RELATED: Grail's third round of venture capital brings total funding to $ 1.5 billion
"These very promising data indicate that a very specific blood test for the early detection of cancer is about to become a reality," said study investigator Minetta Liu, who holds the ## 147 ## # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # 39, a research chair and professor in the Mayo Clinic's Department of Oncology.
"The exceptional accuracy in determining the tissue at all stages for early stage malignancies with significant cancer mortality suggests that, if a cancer is detected, the test will indicate the origin of the tumor in the majority of cases, "said Liu. "This factor is essential to streamline the clinical assessment."
In addition, the low rate of false positives is a strong point for the company.
"When we embarked on this adventure, we knew that to be successful, a blood screening tool would need to detect clinically important cancers and not contribute to the overdiagnosis of indolent cancers in the early stages," Klausner said.
The data come from a pre-planned sub-study of the current GCAC trial, which enrolled approximately 15,000 cancer and non-cancer participants in the United States and Canada. The results reported to ASCO this year are from a first analysis of the training phase of the sub-study, involving 1,422 patients with more than 20 cancer types as well as 879 participants without any diagnosis.
RELATED: Using water and gold, Australian researchers discover a "universal biomarker of cancer"
At last year's ASCO meeting, Grail presented initial GCAC data demonstrating that its concept was consistent: its sequencing tests yielded detection rates ranging from 38% to 51%. % in 127 participants with early-stage lung cancer, including adenocarcinoma, small-cell squamous tumors – with a specificity of 98%.
Since then, Grail has refined his approach by targeting the measurements of DNA methylation – the body's natural processes that regulate gene expression – instead of the genetic code itself. Methylation may present abnormal models of cancer, which may contribute to disease growth by silencing tumor suppressor genes.
[ad_2]
Source link